HM
BLACR

Howard Marks’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Howard Marks’s Portfolio BLACR Stock Details BLACR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-175,000
Closed -$28.9K – 262
2023
Q1 		$28.9K Buy
+175,000
New +$27.2K ﹤0.01% 297

Other funds holding BLACR

HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
ETH
Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

Howard Marks's BLACR Position: Q2 2023 in Review

Howard Marks sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q2 2023, closing a stake of 175,000 shares — an estimated $28.9K sold.

Howard Marks first reported a position in BLACR in Q1 2023 and held it in 1 quarter. The position peaked at $28.9K in Q1 2023. 22 funds tracked by Wall St. Rank hold BLACR as of Q2 2023.

  • Howard Marks reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q2 2023 after selling out during the quarter.
  • Howard Marks sold 175,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q2 2023, an estimated $28.9K.
  • Howard Marks first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 1 quarter.
  • Howard Marks's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $28.9K in Q1 2023.
  • 22 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q2 2023.

Based on Oaktree Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.